A Study To Evaluate Methods To Evaluate Back Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT01045993
First received: January 8, 2010
Last updated: February 21, 2013
Last verified: February 2013
  Purpose

The study is designed to assess methods used in clinical research.


Condition Intervention
Pain
Device: Heat Device
Device: Sham Device
Drug: marketed analgesic
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Time to First Perceptible Relief (Confirmed by Meaningful Relief) [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 4 hours ] [ Designated as safety issue: No ]
    "First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon & Lee.


Secondary Outcome Measures:
  • Time to Meaningful Relief [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 4 hours ] [ Designated as safety issue: No ]
    Time to "meaningful relief" defined as elapsed time from start of treatment until participant depressed the second stopwatch indicating "meaningful relief" (meaningful to participant). Participant consider censored if participant did not depress the stopwatch by end of 4-hour in-patient evaluation, or became a treatment failure (rescue or discontinuation) during the time prior to depressing the second stopwatch. Censoring was at time of dropout if participant withdrew for non-efficacy related reasons during the 4-hour in-patient portion of the study. CI calculated using method of Simon & Lee.

  • Time Weighted Sum of Pain Relief From 0 Through 8 Hours (TOTPAR 0-8) [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 8 hours ] [ Designated as safety issue: No ]
    TOTPAR 0-8 sum of pain relief from 0 through 8 hours, weighted by the time duration between the current timepoint and the previous timepoint. Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief. Total possible score 0 to 40; higher score indicated better relief.

  • Time Weighted Sum of Change From Baseline in the Back Stiffness Score Over 8 Hours [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 8 hours ] [ Designated as safety issue: No ]
    Time weighted sum of change calculated as sum of change from baseline in back stiffness scores from 0 through 8 hours, weighted by time duration between current timepoint and previous timepoint. Based on hourly (from baseline) back stiffness assessment rating from 0 (no muscle stiffness) to 100 (most possible muscle stiffness). Sum of change derived by subtracting score at post-dosing time point from baseline score. Total possible score -800 to 800; higher positive value was indicative of greater improvement.

  • Time to Treatment Failure [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 8 hours ] [ Designated as safety issue: No ]
    Time to treatment failure defined as time from dosing to the time of rescue medication within the scheduled duration of the study (8 hours); or for participants who withdrew from the study due to lack of efficacy without taking rescue medication, the time of the last assessment was considered the time to treatment failure; or if participant did not take rescue medication, or did not discontinue due to lack of efficacy, the time to treatment failure was considered censored at 8 hours (the scheduled duration of the study).

  • Individual Time-Point Pain Relief Scores [ Time Frame: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes ] [ Designated as safety issue: No ]
    Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief.

  • Change From Baseline in Individual Time-point Back Stiffness Scores [ Time Frame: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes ] [ Designated as safety issue: No ]
    Low back muscle stiffness rated hourly (from baseline) by the participant by placing a line on a visual analog scale (VAS) from 0 millimeters (mm) to 100 mm in length with 0=no muscle stiffness up to 100 (most possible stiffness).

  • Change From Baseline (Bsl) in Combined Flexibility Score: Extension [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum extension (as if performing a sit-up) of 20 degrees movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees minus 5, and x degrees plus 5. Flexibility score derived using standardized value and VAS score (participant rating of pain by marking level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for extension flexibility were average of the extension flexibility data on the combined score (range -66 to 552); higher value indicated greater improvement.

  • Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum side-to-side movement of plus or minus (+/-) 10 degrees for left, and right (L, R), movement. Angle at Bsl and 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain to 100=worst pain). Final derived data for overall flexibility was the average of side-to-side (L, R) flexibility data on the combined score (range -81 to 264); higher value=greater improvement.

  • Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum rotation at waist of plus or minus (+/-) 30 degrees for left, and right (L, R), movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for overall flexibility were the average of rotation (L, R) flexibility data on combined score (range -80 to 155); higher value=greater improvement.

  • Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Extension [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement of 20 degrees for extension (as if performing a sit-up) to the degree of movement at which participant perceives discomfort or pain. Higher score indicated greater improvement.

  • Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Side-to-Side [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement +/- 10 degrees for left, and right, side-to-side movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right side-to-side scores. Higher score indicated greater improvement.

  • Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Rotation [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum rotation at waist of +/- 30 degrees for left, and right, movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right rotation scores. Higher score indicated greater improvement.

  • Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum extension of 20 degrees movement (as if performing a sit-up). When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Higher score indicated greater discomfort/pain.

  • Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum side-to-side movement of +/- 10 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

  • Change From Baseline in Pain Measurement for Flexibility Measure: Rotation [ Time Frame: Baseline (time of wrap application or oral treatment administration) and 4 hours ] [ Designated as safety issue: No ]
    Flexibility assessed using Paris Plinth table with maximum rotation at waist of +/- 30 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.

  • Number of Participants Per Categorical Score for Global Assessment of Study Treatment [ Time Frame: Baseline (time of wrap application or oral treatment administration) up to 8 hours ] [ Designated as safety issue: No ]
    At hour 8, or at the time of rescue, if it occurred, participants performed a global assessment in their diary in response to the question: How would you rate the study treatment as a pain reliever? Very Poor=0, Poor=1, Fair=2, Good=3, Very Good=4, Excellent=5.


Enrollment: 61
Study Start Date: February 2010
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Heat device
Device: Heat Device
8-Hour Heatwrap
Other Name: Heatwrap
Sham Comparator: 2
Placebo arm
Device: Sham Device
Inactive wrap worn for 8 hours
Active Comparator: 3
Marketed analgesic
Drug: marketed analgesic
2 x 200 mg ibuprofen tablets
Placebo Comparator: 4
(Oral) Placebo comparator
Drug: Placebo
2 x placebo tablets

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Lower back pain
  • Male or female in generally good health, from 18 to 55 years of age (inclusive)

Exclusion Criteria:

  • Pregnant or lactating
  • Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);
  • Subject has a history of previous back surgery;
  • Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment
  • Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study
  • Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study
  • Has previously been enrolled in this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01045993

Locations
United States, California
Pfizer Investigational Site
Loma Linda, California, United States, 92350
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier: NCT01045993     History of Changes
Other Study ID Numbers: TC-09-20
Study First Received: January 8, 2010
Results First Received: December 5, 2011
Last Updated: February 21, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Pilot Study to Assess Methodologies

Additional relevant MeSH terms:
Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 21, 2014